Analysis on application of novel antitumor drugs in Yichang Central People's Hospital from 2020 to 2023
Objective To analyze the application situation and development tendency of novel antitumor drugs in Yichang Central People's Hospital from 2020 to 2023,and to provide references for the rationally clinical application and standardized management of these drugs.Methods The drug information of novel antitumor drugs in Yichang Central People's Hospital from January 1,2020 to December 31,2023 was collected,and the indexes such as variety number,consumption sum,DDDs,DDC,B/A were retrospectively analyzed.Results From 2020 to 2023,the number of novel antitumor drugs fluctuates,the total sales sum and total DDDs increase year by year,and the DDC of 30 drugs decreases.The consumption sum of bevacizumab,osimertinib,and trastuzumab ranked the top 3.The DDDs of sintilimab increased the fastest,rising to the first place in 2023,and the DDC value decreased from 270.76 in 2020 to 102.86 in 2023,with B/A≥1 for 4 consecutive years.The frequency of clinical use of osimertinib and almonertinib has increased significantly,ranking second and third respectively in DDDs in 2023.Imatinib and gefitinib had high use frequency,low DDC value,B/A greater than 2 in 4 years,good synchronization and high availability.Conclusion The usage of novel antitumor drugs in Yichang Central People's Hospital are gradually increasing,and drug prices are decreasing,which is in line with national policy requirements and the development trend of tumor treatment.
NETL
NSTL
万方数据
